Recently, it has been hypothesized that endothelial cells may also modulate vascular growth, because many anti-proliferative factors such as nitric oxide (NO) and vascular natriuretic peptides are secreted from endothelial cells (1-3). Therefore, it is apparent that dysfunction of endothelial cells may promote abnormal vascular growth such as in atherosclerosis. Especially, vascular remodeling plays an important role in the pathophysiology of atherosclerosis, restenosis and hypertension (4-6). Remodeling is mediated in part by the growth of vascular smooth muscle cells (VSMC). The growth of vascular smooth muscle cells is controlled by a balance of growth inhibitors and growth promoters and, in the normal adult vessel, this balance results in a very low rate of growth of smooth muscle. However, following vascular injury by either mechanical or biochemical means, this balance is shifted such that proliferation of smooth muscle cells occurs (4-6), due to lack of endothelial cells. It is becoming increasingly apparent that among the many factors that may influence vascular structure, vasoactive substances may play a major role. Given the importance of endothelial cells, we hypothesized that rapid regeneration of endothelial cells, not accompanied by VSMC growth, may have therapeutic potential in prevention of abnormal vascular growth such as neointimal formation after angioplasty.
However, there is little knowledge about growth factors that stimulate only endothelial cells, but not VSMC.
From this viewpoint, we have focused on hepatocyte growth factor (HGF) as a candidate.
HGF is known to stimulate hepatocyte growth (7-9). Recent findings suggest that HGF also stimulates various cells such as epithelial cells (10-12). However, it is unclear whether HGF can modulate vascular growth in vitro and in vivo. In order to examine the possible function of HGF in vascular tissues, in this study we examined 1) the biochemical and physiological effects of HGF on endothelial cells and VSMC, 2) the existence and regulation of a local HGF system in vascular tissues, 3) potential role of HGF in vascular disease, and 4) the clinical significance of HGF in hypertension.
HGF is an endothelium-specific growth factor
The concept of the local control of vascular function by locally synthesized compounds has been recently described.
Locally synthesized growth factors may play a major role in the regulation of both vascular tone and structure.
On the other hand, multiple endothelium-derived substances (PGI2, NO, CNP) also have profound influences on vascular smooth muscle function (4-6). Moreover, following vascular injury (by denuding endothelial cells), locally synthesized cytokines and growth factors contribute to the development of neointimal lesions (13, 14) . These local systems appear to be independently regulated by regional factors and may play important physiologic and pathophysiologic roles. Indeed, co-culture of rat coronary endothelial cells with rat VSMC resulted in a significant decrease in DNA synthesis of VSMC (Fig. 1) . The same inhibitory effects of endothelial cells were also observed in co-culture with neointimal VSMC from balloon-injured carotid artery which are known to secrete many growth factors in an autocrine-paracrine manner (15). Similarly, co-culture of human endothelial cells with human VSMC resulted in a significant decrease in DNA synthesis of VSMC. These results suggest the therapeutic potential of endothelial cells. Given the importance of endothelial anti-proliferative actions, seeding or regeneration of endothelial cells may have therapeutic actions against abnormal VSMC growth. From this viewpoint, it would be of interest to seek an endothelial cell-specific growth factor that does not stimulate VSMC growth.
HGF is a mesenchyme-derived pleiotropic factor which regulates cell growth, cell motility, and morphogenesis of various types of cells, and is thus considered a humoral a b mediator of epithelial-mesenchymal interactions responsible for morphogenic tissue interactions during embryonic development and organogenesis (16) (17) (18) (19) . Initially, we examined the effect of exogenously added recombinant HGF on human endothelial cell growth. HGF stimulated DNA synthesis in a dose-dependent manner. Similarly, bFGF and VEGF also stimulated DNA synthesis in endothelial cells. However, DNA synthesis stimulated by HGF was significantly greater than that stimulated by bFGF or VEGF. Endothelial cell numbers were also increased by the addition of HGF, bFGF or VEGF (Fig. 2) . HGF was most potent in stimulating endothelial cell growth as compared to bFGF and VEGF (15, 20) . In contrast, HGF or VEGF did not stimulate DNA synthesis in VSMC. However, the addition of exogenous bFGF resulted in a significant increase in DNA synthesis.
Overall, HGF has the characteristics of an endothelium-specific growth factor the same as VEGF secreted from VSMC, and to act on endothelial cells (21, 22) . Of importance, HGF was the most potent mitogen as compared to bFGF and VEGF.
Presence of local HGF system in endothelial cells and VSMC Many growth factors have been postulated to work local vascular modulators in the autocrine-paracrine manner. It is well known that HGF is synthesized in large amounts in the liver and secreted into the blood. However, HGF transcripts and immunoreactive peptide can also be found in numerous locations including the kidney and lung (10-12). Moreover, its specific receptor, c-met, has been shown to be expressed in many target organs including brain and kidney (10) (11) (12) . This has led to the speculation that locally synthesized HGF may influence local functions.
However, this hypothesis has not been examined previously.
Therefore, we investigated endogenous HGF production and HGF receptor in vascular tissues.
Indeed plasty (24) (25) (26) . Our studies documented a marked reduction of local HGF production by TGF-fl and Ang II treatment in endothelial cells and VSMC. On the other hand, exogenous addition of recombinant rat HGF stimulated local human HGF release into the culture medium both in human endothelial cells and human VSMC, since the anti-HGF antibodies used in this study do not cross react with HGF of other species (27). This phenomenon provides the interesting hypothesis that HGF itself regulates local HGF production by auto-looped positive feedback, and works in an autocrine-paracrine manner. The break of this autocrine-loop, which maintains endothelial cell growth, by TGF-jS and Ang II may result in the abnormal growth of VSMC (Fig. 3) . The promoter region of HGF gene contains various binding sites for transcriptional factors, e.g., interleukin 6 response elements, binding sites for NF-IL 6, a TGF-j3 inhibitory element, and a cAMP. responsive element (28). Probably, TGF-/3 inhibits HGF production through a TGF-fl inhibitory element at the transcriptional level.
What is the potential physiological role of the local HGF system ? TNF-a has been reported to cause cell death through its apoptotic actions (29), and has physiological roles in the pathogenesis of vascular lesion formation (30). Serum-free treatment is also a mediator of apoptosis in endothelial cells (31). Therefore, we tested the stimulatory effect of HGF under these conditions. Of interest, HGF could abrogate the decrease in DNA synthesis and cell death of endothelial cells mediated by TNFa and serum-free treatment.
In contrast, VEGF failed to show no prevention of cell death in endothelial cells. On the other hand, bFGF as well as HGF prevented cell death mediated by serum-free condition.
Currently, bFGF only is known to prevent apoptosis of endothelial cells mediated by serum-free condition (31). An additive effect of HGF and bFGF was observed in the prevention of endothelial cell death, equivalent to the effect of serum treatment.
HGF should be classed as a new member of the growth factors with anti-cell death actions.
More importantly, we demonstrated that high D-glucose, but not mannitol and L-glucose, induced aortic endothelial cell death and L-glucose, induced aortic endothelial cell death, probably apoptosis, which was attenuated by addition of recombinant HGF, and stimulated VSMC growth (32). Local HGF production in endothelial cells and VSMC was markedly suppressed by high D-glucose, probably due to increased TGF-j3 concentration. These results suggest that decreased local HGF production may promote the progression of arteriosclerotic vascular changes in diabetes mellitus.
The mechanisms by which HGF prevented endothelial cell death mediated by these conditions are unclear in this study. HGF is known to stimulate phosphatidylinositol-37-kinase (PI3K), protein tyrosine phosphatase 2, phospholipase C-r, pp 60C and grb2/hSos1 (33-36). Moreover, HGF also stimulated the rho-and ras-mediated signal transduction pathway, resulting in an increase in actin fibers (37, 38). The activation of these signal transduction pathways suggests that HGF will act to prevent cell death. Recently, apoptotic changes in endothelial cells and VSMC have been reported in atherosclerotic lesions and neointimal formation after angioplasty in vivo (39, 40). Lack and/or release of growth factors such as HGF and bFGF may promote the apoptosis in vascular lesions, suggesting the potential role of HGF in the pathophysiology of vascular diseases. 
Potential gene therapy of restenosis after angioplasty by HGF
Given the importance of local HGF production in vascular cells, we examined gene transfer of human HGF into endothelial cells and VSMC, to study the role of endogenous local HGF production.
What is the importance of this local synthesis of HGF ? Although the expression of HGF in the vasculature is orders of magnitude lower than that observed in the liver, due to the limited extracellular volume within the vessel wall, low expression of HGF may result in high extracellular levels of the cytokine. Moreover, the ability of the local tissues to respond to changes in the local environment allows the rapid regulation of local function. To pursue these questions, we have examined the consequences of HGF expression in vascular cells in cell culture. Over-expression of HGF transgene resulted in a significant increase in endothelial cell numbers (41). Interestingly, this mitogenic effect was significantly stronger than that of exogenously added recombinant human HGF at concentrations of 10 and 100 ng/ml. Our data showed a marked increase in rat immunoreactive HGF in cells transfected with human HGF vector. HGF may exert auto-looped positive feedback on HGF production, consistent with findings of earlier experiments that recombinant HGF up-regulated endogenous HGF production in VSMC.
Another aim of this study was to investigate the eventual possibility of gene therapy in vascular diseases.
We have successfully reported gene therapy for restenosis after angioplasty using transgenes and ODN-based technology (42-45). However, none of these strategies has been reported to induce regeneration of endothelial cells. As mentioned earlier, endothelial cells can secrete biological substances to inhibit VSMC growth and vasodilating factors.
Therefore, it is logical that rapid regeneration of endothelial cells has potential therapeutic value against VSMC proliferation (in restenosis after angioplasty). The stimulatory action of HGF gene transfer could also be observed in co-culture using human cells to investigate its potential therapeutic value in human vascular diseases (Fig. 4) . In the co-culture system with human VSMC transfected with HGF vector, the cell growth of quiescent non-transfected human endothelial cells was significantly increased.
These results demonstrated that endothelial cells and VSMC directly transfected with HGF expression vector exhibited increases in cell growth of endothelial cells in an autocrine/paracrine manner. Taken together, these findings suggest that local transfection of HGF gene may have potential therapeutic value as gene therapy. Alternatively, HGF has been reported to promote neovascularization (46). Given that administration of bFGF or VEGF into the coronary artery salvaged infarcted myocardium (47, 48), in vivo transfer of HGF gene may salvage myocardial infarction as gene therapy.
HGF is potential index of arteriosclerosis in hypertensive patients
Given the characteristics of HGF as an endotheliumspecific growth factor, we next evaluated the relationship of circulating HGF with blood pressure in normotensive and hypertensive patients.
As described earlier, TGF-j3 and Ang II strongly inhibited HGF production, and HGF itself stimulated HGF production in vascular cells. In atherosclerotic and hypertensive models, TGF-fl activation of the vascular renin angiotensin system and TGF-/3 was also reported in the vasculature (24-26, 49), potentially leading to the down-regulation of local HGF production in vascular tissues.
HGF is suggested to play an important role in tissue regeneration (16) (17) (18) , and systemic HGF may act as a humoral mediator in tissue-regeneration, in addition to autocrine-paracrine local HGF production. Serum HGF concentration has been reported to be elevated in response to organ damage, such as in hepatitis and nephritisumbers (10-12). Recent findings show that HGF may play an important role in tissue regeneration. Together with the in vivo data, we hypothesized that HGF might contribute to the protection or repair of vascular endothelial cells. If so, serum HGF level might be elevated in response to endothelial cell damage induced by hypertension.
To test this hypothesis, we measured serum levels of HGF, Lp(a), PAI-1, tPA, total cholesterol and blood pressure in normotensive individ- Indeed, our clinical data indicated that serum HGF concentration was significantly correlated with BP (Fig. 5) . Elevation of serum HGF concentration can be considered an index of arteriosclerotic vascular changes, although further studies are needed. Alternatively, serum HGF may act protectively against endothelial dysfunction in organs such as the vasculature and kidney. Besides acting as a growth factor, HGF may also have a role in the regulation of thrombosis. HGF belongs to the family of kringle proteins, characterized by a triple disulfide loop structure (kringles), that mediate protein-protein and protein-cell interactions.
However, there was no relationship between serum HGF concentration and concentrations of total cholesterol, t-PA, PAI-1 and Lp(a), which also belong to the kringle family. On the other hand, blood pressure was also not associated with these factors. Thus, serum HGF concentration may be considered as a new index of endothelial dysfunction in hypertensive patients.
Is HGF a potential therapeutic growth factor ?
Overall, we demonstrated that HGF is a novel member of endothelium-specific growth factors whose serum concentration is significantly associated with systolic blood pressure.
Local HGF system may be regulated by various cytokines, including TGF-/3 and angiotensin II, and HGF itself in vascular tissues, suggesting the potential role of HGF as a counter-system against endothelial dysfunction in cardiovascular disease.
As previously described, in vivo gene transfer and transgenic/gene targeting techniques provide us the opportunity to test the in vivo hypothesis related to hypertension. Future studies using in vivo gene transfer approach may offer new aspects of HGF in vascular biology. We speculate that HGF may be a therapeutic growth factor for the treatment of cardiovascular diseases, e.g., restenosis after angioplasty, arteriosclerosis obliterance and myocardial infarction, as shown in Table 1 Moriguchi A, Yamada K, Hayashi S, Yo Y, Nakano H, Matsumoto K, Nakamura T, and Ogihara T : Hepatocyte growth factor (HGF) is a novel member of endotheliumspecific growth factors : Additive stimulatory effect of HGF with basic fibroblast growth factor, but not vascular endothelial growth factor. J Hypertens, 14 : 1067-1072, 1996 (16) Montesano R, Matsumoto K, Nakamura T, and Orci L :
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